Dr Byndloss on the Relationship Between the Gut Microbiome and GI Cancers
August 18th 2023Mariana X. Byndloss, DVM, PhD, discusses how the gut microbiome influences human health, highlighting the relationship between the gut microbiome and a person’s risk for developing gastrointestinal cancers, as well as characteristics of a healthy gut microbiome.
Dr Dholaria on Ongoing Investigations of Talquetamab and Daratumumab in R/R Multiple Myeloma
August 16th 2023Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
Rini Expands on Key Clinical Trial Updates in GU Cancers from the 2023 ASCO Annual Meeting
Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd
Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Assessing HER2 Expression in Metastatic Colorectal Cancer
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study
Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer
Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice
A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Biomarker Testing in Metastatic Colorectal Cancer
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.
Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
June 8th 2023Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.
Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC
June 7th 2023Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.